The randomized phase 2 ROME trial showed that genomically matched, MTB-guided therapy increased overall response rate and progression-free survival versus standard care in heavily pretreated advanced solid tumors, supporting a tumor-agnostic precision oncology strategy despite unchanged overall survival due to crossover.